Quote
196.52
-8.34 (-4.07%)
We have scored 39 news catalysts on RVMD (RVMD) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in price momentum and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
195.86–205.15
Open
205.13
Prev close
204.86
Volume
1.6M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged RVMD or its network in the window yet.
Show more RVMD articles →Analysts publish price targets on RVMD, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
28 analyst price targets from $151 to $320
as of 2026-09-05
The market is within 7% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about RVMD — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of RVMD, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for RVMD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the 43rd percentile of 28 published models, broadly agreeing with the near-consensus that daraxonrasib is a commercial drug, while explicitly rejecting the bull case for expansion and the bear case on current cash burn.
What the disagreement turns on
Does daraxonrasib's commercial uptake in pancreatic cancer support the base-case revenue assumptions, or does the price require successful expansion into lung cancer and earlier treatment lines to justify its premium? The available data cannot measure this, as prescription volumes and pricing are not wired.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $210 on 2026-09-05 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
